New skin treatment enters testing phase against established drug
NCT ID NCT07411755
Summary
This early-stage study aims to see if a new drug called GS101 works similarly to the existing treatment Dupixent for atopic dermatitis (eczema). Researchers will compare how the body processes both drugs, their safety, and immune responses in 294 healthy adult men in China. This is a first step to determine if GS101 could become another treatment option for this chronic skin condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.